FIG. 1


log2 protein intensity
13
12
11
10
9
8
Baseline
12 Weeks
Baseline
12 Weeks
Baseline
12 Weeks
1 mg/kg
3 mg/kg
10 mg/kg



FIG. 2A

FIG. 2B

FIG. 2C

FIG. 2D


SK-OV-3
Non treated 4587.52
Iso-C 3683.78
+IFN-g 22626.94
Count
MFI PD-L1

FIG. 2E


A549
Non treated 5164.65
Iso-C 1943.59
+IFN-g 37371.80
Count
MFI PD-L1

FIG. 3


unactivated
Activated
Donor#1
Donor#2
%Expressing cells
0
5
10
15
20
25
PD-L1
41BB
CD25

FIG. 4A


cancer cells
Non treated
DSP107
αVEGF
αPD-L1
DSP107 + αVEGF
DSP107 + αPD-L1
αPD-L1 + αVEGF
DSP107+ αPD-L1+ αVEGF
% Cytotoxicity
0
10
20
30
40

FIG. 4B


cancer cells
Non treated
DSP107
αVEGF
αPD-L1
DSP107 + αVEGF
DSP107 + αPD-L1
αPD-L1 + αVEGF
DSP107+ αPDL-1+ αVEGF
% Cytotoxicity
0
10
20
30

FIG. 5A


No treatment
DSP107
αPD-L1 (Atezo)
DSP107 + αPD-L1 (Atezo)
% Phagocytosis
0
10
20
30
40
50
****
****
No treatment
5μg/ml DSP107
1μg/ml Atezo
1μg/ml Atezo+5μg/ml DSP107

FIG. 5B


No treatment
DSP107
αPD-L1 (Atezo)
DSP107 + αPD-L1 (Atezo)
#CD11b-CFSE+
0
10000
20000
30000
***
****
No treatment
5μg/ml DSP107
1μg/ml Atezo
1μg/ml Atezo+5μg/ml DSP107

FIG. 6A


No treatment
DSP107
αPD-L1 (Avelu)
DSP107 + αPD-L1 (Avelu)
% Phagocytosis
0
10
20
30
***
***
No treatment
5μg/ml DSP107
0.25μg/ml Avelu
5μg/ml DSP107+0.25μg/ml Avelu

FIG. 6B


No treatment
DSP107
αPD-L1 (Avelu)
DSP107 + αPD-L1 (Avelu)
#CD11b-CFSE+
0
10000
20000
30000
40000
**
*
No treatment
5μg/ml DSP107
0.25μg/ml Avelu
5μg/ml DSP107+0.25μg/ml Avelu